Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab and Incyte announced a clinical trial collaboration to evaluate petosemtamab plus Incyte's KRAS G12D inhibitor INCB161734 and chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer. Genmab will conduct the Phase 1/2 study; Incyte will co-fund the trial and supply INCB161734.
Key figures
- Drug Name
- petosemtamab (GEN1158)
- Phase Of Trial
- Phase 1/2
- Indication
- first-line KRAS G12D-mutated metastatic colorectal cancer
- Combination partner
- INCB161734 plus standard-of-care chemotherapy
- Petosemtamab phase3 trials crc
- 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.